UNSPSC 51393412: Tazifylline hydrochloride

This classification denotes a bronchodilator with the molecular formula C23H32N6O3S.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 409R6U6UEI, chemically known as 1h-purine-2,6-dione, 3,7-dihydro-7-(2-hydroxy-3-(4-(3-(phenylthio)propyl)-1-piperazinyl)propyl)-1,3-dimethyl-, dihydrochloride, (+-)- but more generally known as tazifylline hydrochloride, which bears US NIH Compound Identifier 54423. Most nations, for tariff and trade purposes, schedule tazifylline hydrochloride under HS 29395900 and SITC 54145.

As of Q4 2014, TAZIFYLLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Tazifylline hydrochloride bears US NLM identifiers UMLS ID C0126094 and NCI Concept Code C96197. SMILES: CN1C2C(C(=O)N(C1=O)C)N(CN2)CC(CN3CCN(CC3)CCCSC4CCCCC4)O.CL.CL.

UNSPSC 51393412 Tazifylline hydrochloride, a Commodity code, nominally describes a specific pharmaceutical compound, but recent state and local solicitations tagged under this code show a mismatch with the code's nominal scope. The two recent opportunities on file—a Seminole County, Florida procurement for naloxone and drug deactivation systems, and a Texas Health and Human Services Commission Request for Information on direct-to-manufacturer prescription programs—involve different pharmaceutical products and pharmacy benefit management services rather than tazifylline hydrochloride specifically. The actual work being sourced under this code designation spans pharmaceutical procurement and pharmacy program administration at the county and state level, though the tag appears to reflect broader pharmaceutical purchasing or pharmacy services categorization rather than procurement targeting this particular active pharmaceutical ingredient.

Recent activity shows issuing bodies at both the state health agency level (Texas HHS) and county public health administration (Seminole County), suggesting that pharmaceutical procurement under this code designation spans multiple governance tiers. The Seminole County opportunity (IFB 60459723LAS, due July 26, 2023) sought annual supplies of naloxone and safe drug deactivation systems with quarterly deliveries, while the Texas RFI (HHS0017013, posted April 3, 2026) explored vendor capacity for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager arrangements. Geographic presence is limited to Florida and Texas in the recent record. The mismatch between the code's pharmaceutical-ingredient specificity and the operational scope of recent solicitations suggests this code may be misapplied to broader pharmacy procurement categories, or the code's actual use has drifted from its nominal definition in state and local practice.